Literature DB >> 3406414

Field-cycling relaxometry: medical applications.

P A Rinck1, H W Fischer, L Vander Elst, Y Van Haverbeke, R N Muller.   

Abstract

Relaxometry between 10 kHz and 200 MHz (0.2 mT and 4.7 T) with a field-cycling device and a high-field-strength magnetic resonance (MR) unit permitted the determination of longitudinal relaxation rates of tissues and chemical compounds at numerous field strengths. The resulting nuclear magnetic relaxation dispersion profiles allowed the prediction of tissue contrast and efficacy of contrast agents at any field strength. Pure T1 contrast of normal brain tissue and pathologic lesions (multiple sclerosis, astrocytoma) increased from low field strengths to a maximum between 10 and 20 MHz and decreased afterward. Quadripolar dips reflecting the interaction between water and nitrogen atoms of the protein backbone appeared at 2.15 and 2.8 MHz, reducing T1 and opening the possibility of shorter imaging times and better tissue discrimination at these field strengths. Furthermore, it was shown that zero T1 contrast between normal and pathologic tissue samples may exist at certain field strengths. Gadolinium diethylenetriaminepentaacetic acid and gadolinium tetraazacyclododecanetetraacetic acid provided different contrast enhancement depending on the field strength.

Entities:  

Mesh:

Year:  1988        PMID: 3406414     DOI: 10.1148/radiology.168.3.3406414

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

Review 1.  The optimal use of contrast agents at high field MRI.

Authors:  Siegfried Trattnig; Kathia Pinker; Ahmed Ba-Ssalamah; Iris-Melanie Nöbauer-Huhmann
Journal:  Eur Radiol       Date:  2006-03-01       Impact factor: 5.315

2.  Global and local mobility of apocalmodulin monitored through fast-field cycling relaxometry.

Authors:  Valentina Borsi; Claudio Luchinat; Giacomo Parigi
Journal:  Biophys J       Date:  2009-09-16       Impact factor: 4.033

3.  Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T.

Authors:  Pavol Szomolanyi; Martin Rohrer; Thomas Frenzel; Iris M Noebauer-Huhmann; Gregor Jost; Jan Endrikat; Siegfried Trattnig; Hubertus Pietsch
Journal:  Invest Radiol       Date:  2019-09       Impact factor: 6.016

4.  MRI assessment of experimental gliomas using 17.6 T.

Authors:  Marc A Schwarz; Mirko Pham; Xavier Helluy; Arnd Doerfler; Tobias Engelhorn
Journal:  Neuroradiology       Date:  2013-03-10       Impact factor: 2.804

5.  Correlation of relaxometry and histopathology: the transplantable human glioblastoma SF295 grown in athymic nude mice.

Authors:  M Spiller; P C Merker; M J Iatropoulos; S M Childress; G M Williams; S S Kasoff
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  [Use of contrast agent in high-field MRI (3 T)].

Authors:  S Trattnig; A Ba-Ssalamah; I M Nöbauer-Huhmann; M Barth; K Pinker; V Mlynarik
Journal:  Radiologe       Date:  2004-01       Impact factor: 0.635

7.  Variation of the magnetic relaxation rate 1/T1 of water protons with magnetic field strength (NMRD profile) of untreated, non-calcified, human astrocytomas: correlation with histology and solids content.

Authors:  M Spiller; S S Kasoff; T A Lansen; S Rifkinson-Mann; M P Valsamis; S H Koenig; M S Tenner
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Regional T1 relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure.

Authors:  Mekala R Raman; Yunhong Shu; Timothy G Lesnick; Clifford R Jack; Kejal Kantarci
Journal:  Magn Reson Med       Date:  2016-02-17       Impact factor: 4.668

9.  Towards applying NMR relaxometry as a diagnostic tool for bone and soft tissue sarcomas: a pilot study.

Authors:  Elzbieta Masiewicz; George P Ashcroft; David Boddie; Sinclair R Dundas; Danuta Kruk; Lionel M Broche
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

10.  Brain tumours at 7T MRI compared to 3T--contrast effect after half and full standard contrast agent dose: initial results.

Authors:  Iris-Melanie Noebauer-Huhmann; P Szomolanyi; C Kronnerwetter; G Widhalm; M Weber; S Nemec; V Juras; M E Ladd; D Prayer; S Trattnig
Journal:  Eur Radiol       Date:  2014-09-07       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.